Short Term Intensified Pembrolizumab (Keytruda) and Tivozanib for High-Risk Renal Cell Carcinoma - STRIKE

Disease Sites:

Kidney (Renal Cell)

Staging:

Phase III

Age Group:

Adults

Therapies:

Not Available

Drugs:

Pembrolizumab, Tivozanib

Principal Investigator(s):

Tan, Alan

Scope:

National

Participating Institutions:

Vanderbilt University

Open Date:

07-25-2025

Trial Type:

Treatment

Protocol ID:

ALLUROA032201

National Clinical Trial ID:

NCT06661720

Eligibility

Ages Eligible for Study:

Not Available

Genders Eligible for Study:

Not Available

Accepts Healthy Volunteers?:

Not Available